

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Lentz et al.

Application No.: 10/572,521

Filed: May 22, 2006

Title: Soluble phospholipids for use in clotting factor assays

U.S. Patent No.: 7,727,736

Issued: June 1, 2009

Confirmation No: 4732

October 20, 2010

Commissioner for Patents

Attn: Certificate of Correction Branch

P.O. Box 1450

Alexandria, VA 22313-1450


**REQUEST FOR ENTRY OF CERTIFICATE OF CORRECTION UNDER
No. 35 U.S.C. §254 AND 37 C.F.R. §1.322**

Sir:

The Assignee of record for the above-referenced patent hereby requests, pursuant to 35 U.S.C. §254 and 37 C.F.R. §1.322, that a Certificate of Correction be issued. This request is made in order to correct the mistakes incurred through the fault of the U.S. Patent and Trademark Office. The Assignee further draws the Commissioner's attention to the first page of the specification (copy attached) filed March 21, 2006. Please note the additional information in the first paragraph titled "Related Application Information". The mistake appearing in the patent is set forth with correction on the Certificate of Correction attached herewith.

No fee is believed due. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.


Respectfully submitted,


Karen A. Magri
Registration No.: 41,965

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATION OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on October 20, 2010.


Lanie A. Dobson

AP20R03470770 21 MAR 2006

5

SOLUBLE PHOSPHOLIPIDS FOR USE IN CLOTTING FACTOR ASSAYS

10

RELATED APPLICATION INFORMATION

This application is a 35 U.S.C. § 371 national phase application of International Application Serial No. PCT/US2004/030987, filed on September 21, 2004, which claims the benefit of U.S. Provisional Application No.

15 60/504,796, filed September 22, 2003, the disclosures of which are incorporated herein by reference in their entireties.

STATEMENT OF FEDERAL SUPPORT

20 The present invention was made, in part, with the support of grant numbers HL45916 and 5-P01-HL06350 from the National Institutes of Health. The United States government has certain rights to this invention.

FIELD OF THE INVENTION

25 The present invention relates to novel reagents and methods for conducting clotting activity assays, in particular, novel soluble phospholipid reagents and clotting activity assays using the same.

BACKGROUND OF THE INVENTION

30 The traditional "cascade" view of blood coagulation is illustrated in **Figure 1** and consists of two converging pathways: the intrinsic or "contact" pathway was originally defined based on adding clay or other "contact reagents" to blood in a test-tube, and the extrinsic pathway that is now believed to be the pathway by which clotting is initiated following tissue injury. Both of these pathways culminate in the production of blood coagulation factor X_a (FX_a , a serine protease) by pathways that depend on membranes. 35 In one of these, factor IX_a (FIX_a , also a serine protease) and its cofactor factor

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO.: 7,727,736
APPLICATION NO.: 10/572,521
ISSUE DATE: June 1, 2010
INVENTOR(S): Lentz et al.

It is certified that an error appears or errors appear in the above-identified patent
and that said Letters Patent is hereby corrected as shown below:

In the Specification

Column 1, Related Application Information: Please replace the entire paragraph with
the following:

-- This application is a 35 U.S.C. §371 national phase application of
International Application Serial No. PCT/US2004/030987, filed on
September 21, 2004 which claims the benefit of U.S. Provisional
Application No. 60/504,796, filed September 22, 2003, the
disclosures of which are incorporated herein by reference in their
entireties. --

MAILING ADDRESS OF SENDER:
Myers, Bigel, Sibley & Sajovec
P.O. Box 37428
Raleigh, NC 27627